Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE) is pleased to announce a poster presentation by Dr Erika Speath at the prestigious American Society of Clinical Oncology Gastroenterology Cancer Symposium in San Francisco last weekend. The Poster titled “Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk” was authored by GTG’s Science Team including Erika Spaeth, Aviv Gafni, Richard Allman and Gillian Dite.
Highlights:
• The poster demonstrates improved performance, identifying patients at risk of developing colorectal cancer by
expanding number of SNPs from 45 to 144
• The patients in the top risk category showed a 27% improvement compared with the 45 SNP geneType model
• The improved performance was consistent across multiple genetic ancestries, greatly improving the utility of the
test leading to increased surveillance in high risk patients.
• The poster builds on an earlier publication by GTG that validated the geneType model, focusing on its’ ability to
stratify patients at higher risk of developing one of the world’s most common cancers